YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Yarrow Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$19.98+1.67 (+9.12%)
Close on Oct 19, 2026
- Market cap
- $17.14M
- P/E (TTM)
- –
- Dividend yield
- –
Yarrow Bioscience, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q4 22 | TTM Q1 22 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty revenues | $477.00K | $901.00K | $931.00K | $838.00K | $1.11M | $1.02M | $791.00K | $703.00K | $297.00K | $92.00K | $400.00K | 100.0% | -48.8% |
| Product sales, net | – | – | $13.82M | $15.91M | $14.82M | $12.34M | $10.20M | $6.10M | $3.23M | $1.75M | $0 | – | – |
| License revenues | – | – | $0 | – | – | – | $10.00M | – | – | – | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Yarrow Bioscience's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.